Ultragenyx Pharmaceutical | RARE - Loan Capital


Ultragenyx Pharmaceutical reported $1.13B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Immunic USD 0 0 Jun/2024
Insmed USD 542.22M 1.25M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Kyowa Hakko Kirin JPY 24.12B 5.27B Dec/2024
MacroGenics USD 70M 256K Dec/2025
Moderna USD 603M 7M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xoma USD 94.38M 7.82M Sep/2025